AI’s Impact on Elections: New Policy Paper Highlights Urgent Global Challenge
Artificial intelligence (AI) is transforming political campaigns worldwide, creating unprecedented opportunities while amplifying risks for democratic processes. According to the newly launched policy paper, The Pervasive Influence of AI on Global Political Campaigns 2024, AI-driven techniques, such as generative AI (genAI), have revolutionized voter engagement through personalized messaging. However, genAI has also emerged as a double-edged sword: while enabling effective campaigning, it has been a significant source of disinformation, eroding trust in democratic institutions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250122148789/en/
Future Shift Labs Co-founder Sagar Vishnoi addresses IPE25 in Cape Town (Photo: Business Wire)
For instance, the United States, classified as “severely polarized” and ranked 3rd among 28 countries for polarization, illustrates how AI-generated propaganda exacerbates societal divisions. Further, the U.S. ranks 1st in distrust of social media, exposing vulnerabilities to AI-driven disinformation campaigns. Russia’s Foreign Influence and Malign Interference (FIMI) activities have prominently leveraged AI tools to spread targeted propaganda. Generative AI platforms like "Doppelganger" have repeatedly been used to sow disinformation and undermine public trust globally. The study underscores the urgent need for governments to regulate AI in elections to prevent future misuse and safeguard democratic integrity.
The policy paper, authored by Alisha Butala, Dr. Christopher Nehring, and Mateusz Łabuz, was developed by Future Shift Labs, a global think tank exploring AI and governance. Officially unveiled on the 23rd of January at the IPE Campaign Expo 2025 in Cape Town, South Africa, the paper provides actionable insights and global case studies. It emphasizes the importance of clear regulations, ethical standards, and investment in public education to combat AI-enabled electoral interference.
Nitin Narang, Founder of Future Shift labs who played a pivotal role in bringing this project to fruition, remarked: "At its core, this research is about people - voters, citizens, and communities. Our team's work is driven by a shared commitment to understanding how AI is reshaping our democratic landscape. By shedding light on these critical issues, we hope to contribute to a more informed, inclusive, and resilient global conversation."
Dr. Israel Govender, a thought leader in technology governance, added: “As we reflect on AI's rapid evolution, our choices today will shape the future of democracy. This research provides a critical perspective on the impact of technology on our values and institutions, serving as a valuable resource for responsible innovation.”
Sagar Vishnoi, Co-founder of Future Shift Labs, and Glen Mpani, organizer of IPE 2025, were present at the launch, reinforcing the think tank's commitment to fostering global discussions on AI governance, transparency, and accountability. Vishnoi notes "Blockchain technology will become the base for other applications in political campaigns, blending seamlessly into the ecosystem, much like AI's current role."
Future Shift Labs is an emerging global think tank dedicated to advancing AI policies and integrating digital statecraft with cutting-edge technologies. The IPE Campaign Expo 2025, renowned for showcasing political innovations, and Kairos Communications, as the principal partner, provided the perfect platform for this milestone launch.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250122148789/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Enginzyme and AGC Create Scalable Process for Key mRNA Ingredient12.1.2026 06:00:00 CET | Press release
At the mRNA Health conference in Berlin, enginzyme and AGC Inc. presented a scalable process to produce a key mRNA vaccine and therapy ingredient, N1-methylpseudouridine-5'-triphosphate (m¹ΨTP). The rapid growth of mRNA-based vaccines and therapeutics has driven significant demand for modified nucleotides like m¹ΨTP, which enhances mRNA stability and expression, while reducing immunogenicity. Enginzyme is a deep-tech company delivering optimized biomanufacturing solutions through cell-free enzyme engineering technology. AGC Inc. is a leading global player in fields spanning from architectural glass to chemicals and life science. AGC Inc. provides services in a wide range of life science fields, from synthetic pharmaceuticals and agrochemicals, to biopharmaceuticals and leading-edge cell and gene therapies, as well as messenger RNAs. The presentation in November detailed the latest collaboration between the companies, with a focus on the biomanufacturing of nucleotides for mRNA therapy,
Ant International Partners with Google’s Universal Commerce Protocol to Expand AI Capabilities12.1.2026 02:15:00 CET | Press release
Ant International, a leading global payment, digitisation, and financial technology provider, is collaborating on the launch of Google’s Universal Commerce Protocol (UCP), a new open standard for agentic commerce that works across the entire shopping journey — from discovery and buying to post-purchase support. UCP establishes a common language for agents and systems to operate together across consumer surfaces, businesses, and payment providers to enable commerce. So instead of requiring unique connections for every individual agent, UCP enables all agents to interact easily. UCP is built to work across verticals and is compatible with existing industry protocols like Agent2Agent (A2A), Agent Payments Protocol (AP2), and Model Context Protocol (MCP). “For agentic commerce to scale, it’s critical for the industry to align on a common set of standards. We are proud to have Ant International endorse the Universal Commerce Protocol as the foundation for that future,” said Ashish Gupta, VP
Torq Secures $140M Series D at $1.2B Valuation to Lead the AI SOC and Agentic AI Era11.1.2026 17:59:00 CET | Press release
Fueled by Massive Customer Adoption of AI Agents, Torq Scales the World’s First True AI SOC Platform and Accelerates Expansion into the U.S. Federal Market Torq, the established Agentic AI security operations pioneer, today announced it has closed a massive $140 million Series D funding round, propelling its valuation to $1.2 billion and total funding to $332M. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112510774/en/ Led by Merlin Ventures—a leading cybersecurity fund renowned for its deep access to the U.S. commercial and Public Sector markets—with participation from all existing investors, including Evolution Equity Partners, Notable Capital, Bessemer Venture Partners, Insight Ventures Partners, and Greenfield Partners, this capital injection is a definitive investment in the future of security. Torq is driving the industry’s critical shift: the complete transformation of the Security Operations Center (SOC) through
Andersen udvider sine kompetencer med tilføjelsen af Scimitar9.1.2026 21:44:00 CET | Pressemeddelelse
Andersen Consulting har indgået en samarbejdsaftale med Scimitar, der er et firma med fokus på at accelerere innovation i biovidenskabsbranchen. Scimitar, der har hovedkvarter i USA, et førende konsulenthus inden for strategieksekvering for biovidenskabsbranchen. Virksomheden er specialiseret i design af driftsmodeller, digital transformation og organisatorisk forandring. Scimitar samarbejder med medicinal- og biotech-virksomheder om at accelerere innovation, styrke den driftsmæssige eksekvering og sikre compliance gennem hele produkters livscyklus. Deres praktiske og samarbejdsorienterede tilgang sikrer løsninger, der ikke blot er formålstjenlige, men også skalerbare. "Virksomheder inden for biovidenskabsbranchen befinder sig i en tid med hurtige videnskabelige fremskridt, stigende regulatorisk kompleksitet og et voksende behov for operationel agilitet, samtidig med at de holdes op mod de højeste standarder for patientsikkerhed og dataintegritet," udtaler Ramy Khalil, CEO i Scimitar.
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release
Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom